Search results for "CORT"

showing 10 items of 3558 documents

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease

1999

BACKGROUNDCrohn’s disease is a chronic inflammatory disease of the alimentary tract. Azathioprine is an effective agent in the management of chronic active Crohn’s disease leading to long term remission of disease activity. Such treatment leads to limited efficacy or side effects in a small subset of patients.AIMSTo compare efficacy and side effects of treatment with azathioprine plus corticosteroids versus mycophenolate mofetil (MMF) plus corticosteroids in patients with chronic active Crohn’s disease.METHODSSeventy patients with chronic active Crohn’s disease (Crohn’s disease activity index (CDAI) greater than 150) were randomised for treatment with azathioprine/cortisone or MMF/cortisone…

medicine.medical_specialtyCrohn's diseaseHepatologybusiness.industrymedicine.drug_classChronic ActiveInflammation and Inflammatory Bowel DiseaseGastroenterologyAzathioprineDiseaseMycophenolatemedicine.diseaseGastroenterologydigestive system diseasesMycophenolic acidSurgeryInternal medicinePrednisoloneMedicineCorticosteroidCortisonebusinessAdverse effectmedicine.drugGut
researchProduct

18-hydroxylation in the Y-1 adrenal cell line: response to ACTH and to culture conditions.

1992

The 18-hydroxylation of deoxycorticosterone in the Y-1 adrenal cell line was studied under various incubation and cell culture conditions and compared to 11 beta-hydroxylation. Repeated incubation of the substrate increased both 18- and 11 beta-hydroxylation in the Y-1 cells. Furthermore, both 18- and 11 beta-hydroxylation were increased with increased serum concentration and prolonged incubation time. While the increase in 11 beta-hydroxylation seemed to be independent of the type of serum, 18-hydroxylation was much more important in cells cultured in fetal or newborn calf serum supplemented medium than in those cultured in horse serum supplemented medium. As expected, ACTH treatment incre…

medicine.medical_specialtyCytochromeEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryHydroxylationBiochemistryHydroxylationchemistry.chemical_compoundMiceEndocrinologyAdrenocorticotropic HormoneCytochrome P-450 Enzyme SystemInternal medicineAdrenal GlandsmedicineAnimalsCytochrome P-450 CYP11B2DesoxycorticosteroneMolecular BiologyIncubationCells CulturedFetusbiologyDose-Response Relationship DrugSubstrate (chemistry)Cell BiologyFetal BloodIn vitroCulture MediaSteroid hormoneEndocrinologyBloodchemistryCell cultureSteroid Hydroxylasesbiology.proteinMolecular MedicineSteroid 11-beta-HydroxylaseThe Journal of steroid biochemistry and molecular biology
researchProduct

Peritoneal cavity phagocytes from the teleost sea bass express a glucocorticoid receptor (cloned and sequenced) involved in genomic modulation of the…

2005

Abstract To gain further insight into the role of cortisol in Wsh innate immune responses, we cloned and sequenced a 2592 bp cDNA from sea bass (Dicentrarchus labrax) peritoneal leukocytes (PCLs) encoding a glucocorticoid receptor (DlGR1). The deduced aminoacid sequence displayed that DlGR1 belong to a multigenic family of steroid hormone receptors, and exhibited high homology (80%) to the Burton’s mouth breeder (Haplochromis burtoni) HbGR1. The DlGR1 functional domains presented homologies with those of several vertebrate species. In situ hybridization assay revealed that DlGR1 was expressed in macrophages and neutrophils from the peritoneal cavity. Since in a previous paper, sea bass PCL …

medicine.medical_specialtyDNA ComplementaryHydrocortisonemedicine.medical_treatmentMolecular Sequence DataDicentrarchus labrax; Peritoneal cavity leukocytes; Phagocytes; Hydrocortisone; RU486; Glucocorticoid receptor; DlGR1; GR cDNA sequence; GR mRNA expressionSequence HomologyGlucocorticoid receptorBiologyDlGR1Peritoneal cavitychemistry.chemical_compoundEndocrinologyGlucocorticoid receptorReceptors GlucocorticoidInternal medicinemedicineAnimalsDicentrarchus labraxPeritoneal cavity leukocyteAmino Acid SequenceSea bassReceptorPeritoneal CavityCells CulturedRespiratory BurstPhagocytesInnate immune systemDose-Response Relationship DrugZymosanZymosanMolecular biologyRespiratory burstSteroid hormoneGR mRNA expressionmedicine.anatomical_structureEndocrinologychemistryPhagocyteLuminescent MeasurementsGR cDNA sequenceAnimal Science and ZoologyBasshormones hormone substitutes and hormone antagonistsStress PsychologicalRU486
researchProduct

Use of leukocyte and platelet-rich fibrin (L-PRF) in periodontally accelerated osteogenic orthodontics (PAOO): clinical effects on edema and pain

2015

Background Demand for shorter treatment time is common in orthodontic patients. Periodontally Accelerated Osteogenic Orthodontics (PAOO) is a somewhat new surgical procedure which allows faster tooth movement via combining orthodontic forces with corticotomy and grafting of alveolar bone plates. Leukocyte and Platelet-Rich Fibrin (L-PRF) possess hard- and soft-tissue healing properties. Further, evidence of pain-inhibitory and anti-inflammatory potential is growing. Therefore, this study explores the feasibility, intra- and post-operative effects of using L-PRF in PAOO in terms of post-operative pain, inflammation, infection and post-orthodontic stability. Material and methods A pilot prosp…

medicine.medical_specialtyDentistryInflammationOdontologíaFibrin03 medical and health sciences0302 clinical medicineEdemaBiomaterials and Bioengineering in DentistrymedicineGeneral DentistryDental alveolusOrthodonticsbiologybusiness.industryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Complete resolutionCiencias de la saludPlatelet-rich fibrinSurgery030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASbiology.proteinmedicine.symptombusinessWound healingCorticotomy
researchProduct

Therapeutic use of hyaluronic acid fillers in the treatment of corticosteroid-induced skin and subcutaneous atrophy

2016

Corticosteroid injection–related tissue atrophy might cause permanent skin and soft tissue deformities1 due to several factors, most importantly fibroblast inhibition and decreased Type I collagen synthesis. Correction of these deformities is challenging and is mostly based on volume replacement with lipofilling or other methods. Clinical observations and research have shown that injection of stabilized hyaluronic acid (HA) induces collagen synthesis, partially restoring dermal matrix components, and eventually producing a permanent effect.2–5 Based on these data, we hypothesize that HA injections might successfully treat atrophic tissue changes caused by corticosteroid injection. We descri…

medicine.medical_specialtyDermal FillerEstheticsLipodystrophymedicine.drug_classInjections SubcutaneousSettore MED/19 - Chirurgia PlasticaBiocompatible MaterialsDermatologyCosmetic TechniquesAdrenal Cortex HormoneInjections SubcutaneouDermal Fillers030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtrophyIn vivoAdrenal Cortex HormonesDermal FillersHyaluronic acidmedicineHumansButtocksHyaluronic AcidBiocompatible MaterialCosmetic Techniquebusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseDermatologymedicine.anatomical_structureCosmetic Techniqueschemistry030220 oncology & carcinogenesisCorticosteroidButtocksSurgeryFemaleLipodystrophyAtrophybusinessEstheticHuman
researchProduct

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Expressional down-regulation of neuronal-type nitric oxide synthase I by glucocorticoids in N1E-115 neuroblastoma cells.

1998

Neuronal-type nitric oxide synthase (NOS I) is involved in ischemia-induced brain damage, and glucocorticoids have been reported to protect from brain damage. This prompted us to investigate if the activity or expression of NOS I was influenced by glucocorticoids. We used the murine neuroblastoma cell line N1E-115 as our experimental model. Short-term incubation (30 min) of the N1E-115 cells with dexamethasone (10 nM to 1 microM) or hydrocortisone (100 nM to 10 microM) did not change the enzymatic activity of NOS I. However, the glucocorticoids inhibited NOS I mRNA expression in a concentration-dependent fashion (down to 53.3 +/- 2. 5% of control). In time-course experiments with 100 nM dex…

medicine.medical_specialtyDown-RegulationNitric Oxide Synthase Type IBiologyNitric OxideDexamethasonechemistry.chemical_compoundMiceNeuroblastomaInternal medicinemedicineTumor Cells CulturedAnimalsRNA MessengerGlucocorticoidsDexamethasonePharmacologyNeuronsMessenger RNAAntiglucocorticoidMifepristoneNitric oxide synthaseBlotEndocrinologychemistryCell culturebiology.proteinMolecular MedicineNitric Oxide SynthaseGlucocorticoidmedicine.drugMolecular pharmacology
researchProduct

Angiotensin converting enzyme gene polimorfism and central obesity: relationship with blood pressure and left ventricular structure and function

2001

medicine.medical_specialtyEjection fractionMegalencephalic leukoencephalopathy with subcortical cystsbiologybusiness.industryDiastoleAngiotensin-converting enzymemedicine.diseaseInappropriate sinus tachycardiaBlood pressureWaist–hip ratioEndocrinologyInternal medicineInternal Medicinemedicinebiology.proteinCardiologySystolebusinessAmerican Journal of Hypertension
researchProduct

2014

Bipolar disorder is characterized by a functional imbalance between hyperactive ventral/limbic areas and hypoactive dorsal/cognitive brain regions potentially contributing to affective and cognitive symptoms. Resting-state studies in bipolar disorder have identified abnormal functional connectivity between these brain regions. However, most of these studies used a seed-based approach, thus restricting the number of regions that were analyzed. Using data-driven approaches, researchers identified resting state networks whose spatial maps overlap with frontolimbic areas such as the default mode network, the frontoparietal networks, the salient network, and the meso/paralimbic network. These ne…

medicine.medical_specialtyElementary cognitive taskMultidisciplinaryBipolar I disorderResting state fMRICognitionmedicine.diseaseSchizophreniamedicineBipolar disorderPsychiatryPsychologyPrefrontal cortexNeuroscienceDefault mode networkPLOS ONE
researchProduct